emedastine
Trade name: emadine
Small moleculeapproved
Approved
Dec 29, 1997
Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfavorable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration. — NCATS
Clinical trial activity
1 trials · 2 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Mar 31, 2022 (NCT05318157)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Approval history
- approvedDec 29, 1997
Chemistry & pharmacology
Loading structure…
SMILES
CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21- Mol. weight
- 302.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL594 ↗
- WikipediaEmedastine ↗
- NCATS9J1H7Y9OJV ↗
- ChEMBLCHEMBL2103739 ↗
Also known as
- 1-(2-ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1h-benzoimidazole
- 1-(2-ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1h-benzoimidazole
- 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
- 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
- 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate
- 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)benzimidazole
- 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)benzimidazole
- al-3432a
- al-3432a
- daren
- emadine
- emadine
- emadine
- emadine
- emadine
- emedastina
- emedastina
- emedastine
- emedastine
- emedastine
- emedastine
- emedastine
- emedastine
- emedastine
- emedastine
- emedastine
- emedastine difumarate
- emedastine difumarate
- emedastine difumarate
- emedastine difumarate
- emedastine difumarate
- emedastine difumarate ophthalmic solution
- emedastine difumarate ophthalmic solution
- emedastine difumarate ophthalmic solution
- emedastine difumarate ophthalmic solution
- emedastine difumarate ophthalmic solution
- emedastine fumarate
- emedastinum
- emedastinum
- kb 2413
- kb-2413
- kg 2413
- kg-2413
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05318157 | Phase 4 | Mar 31, 2022 | Capital Medical University, Peking University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1